Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Reset

Download Results Save this Search

Project # Sort descending	Project Title	Research Focus Area	Research Program	Administering IC	Institution(s)	Investigator(s)	Location(s)	Year Awarded
1R21DA057598-01	Tracking the Opioid Epidemic with Social Media: An Early Warning System	Cross-Cutting Research	Leveraging Existing and Real-Time Opioid and Pain Management Data	NIDA	STANFORD UNIVERSITY	ALTMAN, RUSS BIAGIO	Redwood City, CA	2022
NOFO Title: HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed) NOFO Number: RFA-DA-22-045 Summary: A key component to addressing the current opioid overdose crisis is the ability to track dangerous opioid use in a timely manner so that public health agencies can plan accordingly. Direct reports about drug use and overdoses from social media might provide a useful early warning system that when combined with other sources, can provide policy makers and public health officials with powerful tools for monitoring this public health crisis. This project will explore the usefulness of Twitter and Reddit as a social media component of opioid use surveillance – in particular by monitoring mentions of fentanyl and synthetic opioids at various geographic levels (e.g., local or regional) and over time.
1R21DA057677-01	Developing a Timely Opioid Overdose Detection Tool through a Tribally Engaged Approach	Cross-Cutting Research	Leveraging Existing and Real-Time Opioid and Pain Management Data	NIDA	UNIVERSITY OF CALIFORNIA, SAN DIEGO	GAINES, TOMMI LYNN	La Jolla, CA	2022
NOFO Title: HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed) NOFO Number: RFA-DA-22-045 Summary: Addressing the current opioid overdose crisis requires tracking risky opioid use in a timely manner so that public health agencies can plan accordingly and supply life-saving resources. American Indian Tribes often lack such tools, even though American Indians and Alaska Natives have the highest rates of opioid overdose fatalities. This project will adapt commercialized monitoring technologies for use in Tribal communities, in consultation with affected Tribes. Through a partnership with a Tribal Fire Department and a software company providing data analytics for public safety agencies, this research will build a near real-time opioid overdose dashboard for use within Tribal boundaries. The findings may also improve data collection and outbreak monitoring for other substances, including methamphetamine and cocaine.
1R21DE032531-01	Long-term Opioid Therapy, Depression, and Suicide Mortality Risk in Patients with Head and Neck Cancer	Cross-Cutting Research	Leveraging Existing and Real-Time Opioid and Pain Management Data	NIDCR	DUKE UNIVERSITY	OSAZUWA-PETERS, NOSAYABA	Durham, NC	2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed) NOFO Number: RFA-DE-22-011 Summary: It is unclear if long-term use of opioids by head and neck cancer patients affects risk for depression, which is higher in this population compared to people without cancer. This knowledge could inform interventions such as increased opioid prescription safety or alternative pain management approaches and could thus help reduce the risk for depression-related outcomes. This project will use data from a national cancer database linked to Medicare claims and a Veterans Administration database to determine whether people with head and neck cancer that take opioid medications for more than 90 days have increased risk for new-onset or worsening depression or suicide death.
1R21DE032532-01	Secondary Analysis and Integration of Existing Data Related to Chronic Orofacial Pain and Placebo Effects	Cross-Cutting Research	Leveraging Existing and Real-Time Opioid and Pain Management Data	NIDCR	UNIVERSITY OF MARYLAND, BALTIMORE	COLLOCA, LUANA (contact); DORSEY, SUSAN G	Baltimore, MD	2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed) NOFO Number: RFA-DE-22-011 Summary: Temporomandibular joint (TMJ) disorders, which affect the joint connecting the lower jaw and the skull, are common and difficult chronic pain conditions. Pain management strategies that harness the body’s own pain relief mechanisms (including placebo effects in which pain relief cannot be attributed to a specific treatment), can reduce the severity and duration of TMJ-related chronic pain. Although research suggests that placebo effects may have a genetic basis, few, if any, genetic studies have examined this possibility in individuals with TMJ disorders. This project will use in-depth genetic, sociodemographic, clinical, and psychological data collected from adults with chronic TMJ disorders to better understand how the placebo effect works.
1R21DE032583-01	Predicting Pediatric Sickle Cell Disease Acute Pain Using Mathematical Models Based on mHealth Data	Cross-Cutting Research	Leveraging Existing and Real-Time Opioid and Pain Management Data	NIDCR	VIRGINIA COMMONWEALTH UNIVERSITY	VALRIE, CECELIA R (contact); MCGEE, REGINALD	Richmond, VA	2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed) NOFO Number: RFA-DE-22-011 Summary: Sickle cell disease is an inherited blood disorder affecting about 100,000 Americans and more than 20 million people worldwide. It is caused by a mutation in the gene for beta-globin that results in the characteristic sickled shape of red blood cells, life-long severe pain, and shortened lifespan. Sickle cell disease pain episodes are usually unanticipated, making it hard for people with the condition to manage their pain and putting them at risk for increased use of opioids and poor health outcomes. This project will use existing real-time health data to identify factors that can predict onset, severity, and worsening of daily pain in children with sickle cell disease.
1R21DE032584-01	Identifying Chronic Pain Phenotypes and Treatment Disparities in Adults with Cerebral Palsy	Cross-Cutting Research	Leveraging Existing and Real-Time Opioid and Pain Management Data	NIDCR	UNIVERSITY OF MICHIGAN	PETERSON, MARK D	Ann Arbor, MI	2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed) NOFO Number: RFA-DE-22-011 Summary: Cerebral palsy is the most common physical disability in children. Those who have this condition experience pain throughout their lives. Although opioids are generally not recommended, many adults with cerebral palsy are prescribed them for pain. This project will assess the incidence of chronic pain conditions in adults with and without cerebral palsy as well as measure opioid treatment-related health outcomes in adults with cerebral palsy. This research will also evaluate pain treatment disparities related to race/ethnicity and insurance coverage using national medical claims databases.
1R21HD112210-01	Neurobiology of Pain Experiences in Youth in the ABCD Study	Cross-Cutting Research	Leveraging Existing and Real-Time Opioid and Pain Management Data	NICHD	OREGON HEALTH & SCIENCE UNIVERSITY	WILSON, ANNA CAMILLE	Portland, OR	2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed) NOFO Number: RFA-DE-22-011 Summary: Many millions of Americans experience chronic pain, including about 25 million who report pain that substantially interferes with daily activities and reduces quality of life. Many chronic pain syndromes are more prevalent in females, and the incidence of chronic pain increases dramatically during adolescence. This research will use neuroimaging and other biological, social, and psychological data from a large study of young adolescents with or without pain to identify risk and protective factors for chronic pain.
1R24NS132283-01	PURPOSE: Positively Uniting Researchers of Pain to Opine, Synthesize, and Engage	Cross-Cutting Research	Training the Next Generation of Researchers in HEAL	NINDS	NEUROVATIONS	COVERSTONE, JACOB SUTTON	Napa, CA	2022
NOFO Title: Emergency Awards: HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed) NOFO Number: RFA-NS-22-060 Summary: The Interagency Pain Research Coordinating Committee has identified a need for organized opportunities for early-stage pain researchers to meet and learn from more experienced pain researchers and mentors – who are exiting the field at a faster rate than they are being replaced. This project will create a coordinating center for early-stage pain researchers, with an online networking platform to encourage interactions and collaboration among these scientists. The research will also develop a training curriculum and make it accessible to NIH funded, early-stage pain scientists.
1R41AR080620-01A1	Injectable Ice Slurry Cooling Technology for Treatment of Postoperative Pain	Cross-Cutting Research	Small Business Programs	NIAMS	BRIXTON BIOSCIENCES, INC.	SIDOTI, CHARLES	Cambridge, MA	2022
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) NOFO Number: RFA-NS-20-009 Summary: More than 700,000 total knee replacement surgeries are performed each year in the United States to relieve joint pain in patients with end-stage osteoarthritis or rheumatic arthritis. However, many patients still experience significant pain after this procedure, calling for additional long-lasting, drug-free pain management strategies. This project will develop and test a commercial prototype device for persistent knee pain after total knee replacement. The injection-based method freezes peripheral nerves to reduce pain sensation.
1R41DA047779-01	DEVELOPMENT OF A TRACHEAL SOUND SENSOR FOR EARLY DETECTION OF HYPOVENTILATION DUE TO OPIOID OVERDOSE.	Cross-Cutting Research	Small Business Programs	NIDA	RTM Vital Signs, LLC	Joseph, Jeffrey I	FORT WASHINGTON, MD	2019
NOFO Title: PHS 2018-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) NOFO Number: PA-18-575 Summary: One of the current critical needs in addressing the opioid crisis is the development of new overdose-reversal interventions, including wearable technologies that can detect an (impending) overdose from physiological signals to signal for help, or trigger a coupled automated injection of naloxone. This project tests the approach of monitoring respiration by detecting the sounds of breathing in the trachea. This proposal aims to develop a machine learning algorithm that could process those sounds, detect the kinds of patterns of reduced breathing that occur during an opioid overdose, and design a miniature wireless sensor that could be used to detect those sounds. Such a sensor and algorithm could be a key component to a device to detect and intervene in overdoses.
1R41DA048689-01	BEST-OUD: Behavioral Economic Screening Tool of Opioid Use Disorder for use in clinical practice	Cross-Cutting Research	Small Business Programs	NIDA	BEAM DIAGNOSTICS, INC	SNIDER, SARAH EMILY	Roanoke, VA	2019
NOFO Title: PHS 2018-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) NOFO Number: PA-18-575 Summary: A critical line of defense against opioid use disorder (OUD), one of the nation’s leading preventable causes of death, must be standardized screening provided by the patient’s primary care physician, psychiatrist, and/or counselor. Standardized screening methods for opioids, however, are simply inferior and no gold standards exist. This project aims to develop a validated, theoretically guided tool that provides clinicians with information beyond OUD symptoms using reinforcer pathology, a measure of severity derived from the synergy between excessive delay discounting and high behavioral economic demand. The Behavioral Economic Screening Tool (BEST-OUD) will use these combined measures in a mobile tablet application to enable clinicians to screen for OUD.
1R41DA050364-01	Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain	Cross-Cutting Research	Small Business Programs	NIDA	REGULONIX, LLC	KHANNA	Tucson, AZ	2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) NOFO Number: RFA-DA-19-019 Summary: The increase in prevalence of cancer coupled with an increase in the cancer survival rates due to chemotherapy regimens is transforming cancer pain into a large, unmet medical problem. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting side effect of many cancer drug treatment regimens and is caused in part by alterations in ion channels; blocking or depleting Cav3.2 channels in dorsal root ganglion (DRG) neurons should thus mediate analgesic effects. This proposal aims to develop and test potent, orally available, and selective Cav3.2 channel antagonists, building on the structure of a medicinal plant product—betulinic acid (BA)—that has been identified to be Cav3.2-selective and antinociceptive in CIPN. Such compounds could reduce the reliance on opioids in cancer patients.
1R41DA050386-01	Prevention of renarcotization from synthetic opioids	Cross-Cutting Research	Small Business Programs	NIDA	CONSEGNA PHARMA, INC.	AVERICK, SAADYAH	Pittsburgh, PA	2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) NOFO Number: RFA-DA-19-019 Summary: While the mu opioid receptor (MOR) antagonist naloxone has proven invaluable as an opioid overdose antidote, naloxone suffers from a very short duration of action (half-life is approximately 1 hour) and has been found to be less effective against newer, long-acting opioids, including fentanyl (half-life is approximately 7–10 hours). This leads to a highly lethal and increasingly prevalent phenomenon known as “renarcotization,” wherein an overdose patient revived with naloxone can re-enter an overdose state from residual fentanyl in the body. Thus, there is a critical need to develop a long-acting MOR antagonist formulation that can address renarcotization by providing multi-hour protection. The goal of this project is to reformulate naloxone using FDA-approved microencapsulation technology into a long-acting injectable (LAI) that can provide 12–24 hours of sustained antagonist activity in vivo. It will employ a proprietary Computational Drug Delivery™ software, called ADSR™, to perform in silico formulation optimization as well as to predict its in vitro dissolution and in vivo pharmacokinetic behavior.
1R41NS113717-01	Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain	Cross-Cutting Research	Small Business Programs	NINDS	DOULEUR THERAPEUTICS, INC.	YAKSH, TONY L; CHAKRAVARTHY, KRISHNAN	San Diego, CA	2019
NOFO Title: PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) NOFO Number: PA-18-575 Summary: Chronic persistent post-operative pain (CPOP) is a devastating outcome from any type of surgical procedure. Its incidence is anywhere between 20-85% depending on the type of surgery, with thoracotomies showing one of the highest annual incidences of 30-60%. Given that millions of patients (approximately 23 million yearly based on incidence) are affected by CPOP, the results are increased direct medical costs, increased indirect medical costs due to decreased productivity, and associated negative effects on an individual’s physical functioning, psychological state, and quality of life. Given these extensive public health and economic consequences there is a resurgence of research in the area of preventative analgesia. The goal of this project is to evaluate a novel small molecule antagonist of MD2-TLR4, DT-001 in preclinical models of surgical pain representative of persistent post-operative pain. In collaboration with University of California, San Diego, DT-001 will be evaluated for its ability to block the development of neuropathic pain states. These studies will evaluate dose escalating efficacy of DT001 in rats in formalin and spinal nerve injury (SNI) models using both intrathecal and intravenous routes of administration. Tissues will be preserved to assess functional effects on relevant pain centers for analysis by Raft. With demonstration of efficacy, these studies will determine the optimal dose and route of administration of DT001 and guide a development path to IND and eventually clinical trials.
1R41NS115460-01	Minimally Invasive Intercostal Nerve Block Device to Treat Severe Pain and Reduce Usage of Opiates	Cross-Cutting Research	Small Business Programs	NINDS	TAI, CHANGFENG; POPIELARSKI, STEVE	THERMAQUIL, INC.	Philadelphia, PA	2019
NOFO Title: PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) NOFO Number: PA-18-575 Summary: Most of the 200k Americans who undergo thoracotomy each year receive opiates to reduce postoperative pain because clinicians have few non-addictive, cost-effective choices to control the severe pain patients often experience in the first two weeks after surgery. Managing pain post-thoracotomy is critical to enable patients to take deep breaths and remove (via coughing) lung secretions that otherwise significantly increase risk of pneumonia and collapsed lung, hospital re-admission and morbidity. The most severe pain associated with thoracotomy is transmitted along the intercostal nerves, but no long-term analgesic or nerve block device exists that can provide safe and effective long-term reduction of pain. A reversible, patient-controlled, non- addictive, intercostal nerve block device would reduce suffering due to thoracotomy, broken ribs and herpes zoster. In this Phase I project, the team will develop a minimally invasive thermal nerve block device that can control nerve conduction by gently warming and cooling a short nerve segment between room temperature and warm water temperature. This novel approach is based on the discovery that warm and cool temperature mechanisms of nerve block are different and additive, enabling moderate-temperature nerve block by cycling neural tissues slightly above and below body temperature. Reversible thermal nerve blocks represent a completely new approach to managing pain.
1R41NS116784-01	Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy	Cross-Cutting Research	Small Business Programs	NINDS	REGULONIX, LLC	KHANNA, RAJESH	Tucson, AZ	2019
NOFO Title: PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) NOFO Number: PA-17-303 Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is detected in 64% of cancer patients during all phases of cancer. CIPN can result in chemotherapy dose reduction or discontinuation, and can also have long-term effects on the quality of life. Taxanes (like Paclitaxel) may cause structural damage to peripheral nerves, resulting in aberrant somatosensory processing in the peripheral and/or central nervous system. Dorsal root ganglia (DRG) sensory neurons as well as neuronal cells in the spinal cord are key sites in which chemotherapy induced neurotoxicity occurs. T-type Ca2+ channels are critical determinants of increased neuronal excitability and neurotransmission accompanying persistent neuropathic pain. Though Cav3.2 has been targeted clinically with small molecule antagonists, no drugs targeting these channels have advanced to phase II human clinical trials. This proposal aims to explore multicomponent reaction products, for the rapid identification of potent and selective T-type Ca2+ channel antagonists. The work proposed here is the first step in developing non-opioid pain treatments for CIPN. The team anticipates success against paclitaxel-induced chronic pain will translate into other chronic pain types as well, but CIPN provides focus for early stage proof-of-concept.
1R41NS118992-01	Development of selective calpain-1 inhibitors for chronic pain	Cross-Cutting Research	Small Business Programs	NINDS	1910 GENETICS, INC.	NWANKWO, JENNIFER	Cambridge, MA	2021
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed) NOFO Number: NS-20-011 Summary: The need to develop non-opioid therapeutics for chronic pain is greater than ever. One option being explored is inhibiting the activity of calpains – enzymes that have been shown to cause pain in animal models of chronic pain. Using an artificial intelligence (AI)-driven drug discovery platform, researchers have uncovered and validated four calpain-1 inhibitors using biochemical assays. This study by 1910 Genetics Inc. hopes to synthesize multiple analogs of its most potent discovered calpain-1 inhibitor and determine its effectiveness against calpain-2 and certain enzymes that break down proteins. Findings that successfully significantly inhibit calpain-1 in at least one animal model of chronic pain could lead to the first oral, central nervous system penetrating selective calpain-1 inhibitor [non-opioid therapeutic] for chronic pain.
1R41NS127637-01A1	Protease-Activated-Receptor-2 Antagonists for Treatment of Migraine Pain	Cross-Cutting Research	Small Business Programs	NINDS	PARMEDICS, INC.	DEFEA, KATHRYN (contact); DUSSOR, GREGORY O	Temecula, CA	2023
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) NOFO Number: RFA-NS-20-009 Summary: There is a need for additional effective treatments for migraine, which affects more than 36 million people in the United States. This project will develop an oral medication to disrupt the biological processes that drive migraine pain, which include nerve inflammation in response to pain signals.
1R41NS132625-01A1	Opioid-Sparing Non-Surgical, Bioresorbable Nerve Stimulator for Pain Relief	Cross-Cutting Research	Small Business Programs	NINDS	VANISH THERAPEUTICS INC.	CUI, XINYAN TRACY	Mars, PA	2023
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) NOFO Number: RFA-NS-23-007 Summary: Nerve stimulators are devices surgically implanted near a peripheral nerve or on the spinal cord that use electrical signals to reduce the perception of pain. Although these devices can provide effective pain relief to patients, many have high complication rates, resulting from the wire moving, breaking, not working, or the implantable battery pack or permanent wire causing new pain. This project will support the development and animal testing of a peripheral nerve stimulator to treat chronic pain which can be implanted without surgery. Once injected, the device will provide pain relief through electrical stimulation and then be safely degraded and resorbed by the body.
1R42DA049448-01	Reward-based technology to improve opioid use disorder treatment initiation after an ED visit	Cross-Cutting Research	Small Business Programs	NIDA	Q2I, LLC	BOUDREAUX, EDWIN D	Rindge, NH	2019
NOFO Title: Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R41/R42 - Clinical Trial Optional) NOFO Number: RFA-DA-19-015 Summary: Medication-assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of people with OUD access MAT, and treatment non-adherence is common and associated with poor outcomes. This project aims to increase rates of Suboxone (buprenorphine/naloxone) treatment initiation and adherence among OUD patients recruited from emergency and inpatient acute care by enhancing the Opioid Addiction Recovery Support (OARS)—an existing Q2i company technology—with a new evidence-based reward, contingency management (CM) function that allows for the automatic calculation, delivery, and redemption of rewards contingent on objective evidence of Suboxone initiation and adherence.
1R42NS132622-01	Targeting TLR4-lipid rafts to prevent postoperative pain	Cross-Cutting Research	Small Business Programs	NINDS	RAFT PHARMACEUTICALS, LLC	DOUGHERTY, PATRICK M (contact); KOGAN, YAKOV	San Diego, CA	2023
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) NOFO Number: RFA-NS-20-009
1R43AR074369-01	Development of a fixed-dose combination therapy for the treatment of chronic musculoskeletal pain	Cross-Cutting Research	Small Business Programs	NIAMS	NEUROCYCLE THERAPEUTICS, INC.	TOCZKO, MATTHEW ALEXANDER	Sheridan, WY	2019
NOFO Title: PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) NOFO Number: PA-17-302 Summary: Non-steroidal anti-inflammatory drugs (NSAIDs) are a first line pharmacologic pain therapy for chronic musculoskeletal pain, and rheumatoid arthritis (RA) and moderate to severe osteoarthritis (OA) specifically. However, insufficient pain relief by NSAID monotherapy has encouraged the use of combination therapy. Combinations of NSAIDs plus weak opioids are widely used although objective evidence for efficacy is limited and they have many adverse events. A growing body of evidence suggests that ?2/?3 subtype-selective positive allosteric modulators (PAM) of the ?- aminobutyric acid A receptor (GABAAR) may effectively restore central pain regulatory mechanisms thus providing effective relief of chronic pain with reduced prevalence and severity of side-effects. Based on these promising preliminary studies and considerable supporting literature data, the research team will test the hypothesis that combination dosing of TPA-023B with an NSAID will work synergistically to suppress the acute and chronic pain components of chronic musculoskeletal pain.
1R43CA233371-01A1	Inhibiting soluble epoxide hydrolase as a treatment for chemotherapy inducedperipheral neuropathic pain	Cross-Cutting Research	Small Business Programs	NCI	EICOSIS, LLC	BUCKPITT, ALAN R	Davis, CA	2019
NOFO Title: PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) NOFO Number: PA-18-574 Summary: Investigating the broader efficacy of sEH inhibition and specifically our IND candidate, EC5026, has indicated that it is efficacious against chemotherapy induced peripheral neuropathy (CIPN). This painful neuropathy develops from chemotherapy treatment, is notoriously difficult to treat, and can lead to discontinuation of life-prolonging cancer treatments. Thus, new therapeutic approaches are urgently needed. The research team will investigate if EC5026 has potential drug-drug interaction with approved chemotherapeutics or alters immune cells function, and assess the effects of sEHI on the lipid metabolome and probe for changes in endoplasmic reticulum stress and axonal outgrowth in neurons. The team proposes to more fully characterize the analgesic potential of our compound and investigate on and off target actions in CIPN models and model systems relevant to cancer therapy.
1R43CA268700-01A1	Pre-clinical Validation of Phase II Peptide LRP-1 Agonist to Treat and Prevent Chemotherapy Induced Peripheral Neuropathy	Cross-Cutting Research	Small Business Programs	NCI	SERPIN PHARMA, LLC	GELBER, COHAVA (contact); CAMPANA, WENDY M	Manassas, VA	2022
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed) NOFO Number: RFA-NS-20-011 Summary: Some chemotherapy treatments damage nerves outside the brain and spinal cord. This condition, chemotherapy-induced peripheral neuropathy, involves tingling, burning, weakness, or numbness in hands and/or feet and affects nearly 70% of cancer patients receiving chemotherapy. Common pain medications, including opioids, can relieve pain for short intervals but are not suitable for long-term therapy. This project will develop and test a new type of treatment (reduced size cyclic analogs) for this condition. The research will evaluate the ability of this therapy to reduce inflammation and pain, as well as to repair nerve damage.
1R43DA046973-01	Device to Measure Pain using Facial Expression Recognition with Patiene PAINReportitA Tablet	Cross-Cutting Research	Small Business Programs	NIDA	ENSURING, LLC	CHEN, ZHANLI	Seattle, WA	2019
NOFO Title: Development of a Device to Objectively Measure Pain (R43/R44) NOFO Number: RFA-DA-18-012 Summary: Even though pain is a nearly universal experience, objective measurements of pain remain difficult. Given that responding to the opioid crisis will require both better ways to manage pain and better ways to detect drug-seeking behavior, finding approaches to objectively measure pain is crucial. The goal of this project is to develop a product that will objectively measure pain using computer vision and machine learning technologies together with tablet-based self-reported pain data from patients for research or clinical purposes. The product will be low cost, involving one or two cameras to record the video and a computer to analyze the video in almost-real time, and will involve software that can be portable to ordinary personal computers and tablets. The project will capture facial expressions related to genuine pain and integrate it with patients’ self-reported pain data, in order to refine the product and create an objective measure of pain intensity that can be used in clinical settings and test its accuracy. This new tool has the potential to help rectify the poor pain outcomes that still plague Americans with opioid addiction, cancer, and other health conditions in many health care settings.